articleNature MedicineFeb 13, 2024HYBRID OA

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

BBBenjamin BesseEPElvire Pons‐TostivintKPKeunchil ParkSHSylvia HartlPMPatrick M. Forde

Université Paris-Saclay · Institut Gustave Roussy · +34 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L)1 checkpoint inhibitors, alone or with platinum-doublet therapy. However, not all patients derive durable benefit and resistance to immune checkpoint blockade is common. Understanding mechanisms of resistance-which can include defects in DNA damage response and repair pathways, alterations or functional mutations in STK11/LKB1, alterations in antigen-presentation pathways, and immunosuppressive cellular subsets within the tumor microenvironment-and developing effective therapies to overcome them, remains an unmet need. Here the phase 2…

Citation impact

114
total citations
FWCI
28.72
Percentile
100%
References
81
Citations per year

Authors

38

Topics & keywords

Topics
Keywords
  • Durvalumab
  • Medicine
  • Immunotherapy
  • Oncology
  • Internal medicine
  • Lung cancer
  • Cancer
  • Immunology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding